Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities (2016 - 2023)

Historic Total Liabilities for Aytu Biopharma (AYTU) over the last 15 years, with Q4 2025 value amounting to $107.8 million.

  • Aytu Biopharma's Total Liabilities rose 2613.68% to $107.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $107.8 million, marking a year-over-year increase of 2613.68%. This contributed to the annual value of $105.2 million for FY2025, which is 1641.09% up from last year.
  • As of Q4 2025, Aytu Biopharma's Total Liabilities stood at $107.8 million, which was up 2613.68% from $101.8 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Total Liabilities registered a high of $128.4 million during Q1 2021, and its lowest value of $85.5 million during Q4 2024.
  • Its 5-year average for Total Liabilities is $102.8 million, with a median of $101.2 million in 2022.
  • As far as peak fluctuations go, Aytu Biopharma's Total Liabilities surged by 13149.54% in 2021, and later plummeted by 2715.46% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Total Liabilities stood at $118.3 million in 2021, then dropped by 19.16% to $95.6 million in 2022, then grew by 2.9% to $98.4 million in 2023, then fell by 13.14% to $85.5 million in 2024, then grew by 26.14% to $107.8 million in 2025.
  • Its Total Liabilities was $107.8 million in Q4 2025, compared to $101.8 million in Q3 2025 and $105.2 million in Q2 2025.